Drug Search Results
Using advanced filters...
Advanced Search [+]

Exeporfinium chloride

Alternative Names: exeporfinium chloride, xf-73, xf73, xf 73
Clinical Status: Inactive
Latest Update: 2023-10-11
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Cell Wall Degrader

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Nasal

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Destiny Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Surgical Wound Infection|Staphylococcal Infections|Communicable Diseases

Phase 1: Staphylococcal Infections

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

XF-73B07

P2

Completed

Staphylococcal Infections|Communicable Diseases|Surgical Wound Infection

2021-01-04

53%

2022-06-02

Primary Endpoints|Start Date|Treatments

HHSN272201500007I

P1

Completed

Staphylococcal Infections

2015-08-01

2019-03-19

Treatments

XF-73B03

P2

Completed

Staphylococcal Infections

2014-11-01

2019-03-20

Treatments